We are live on ! Find out more
Barclays

Barclays Portfolio holdings

AUM $416B
1-Year Est. Return 33.63%
 

Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.

This Fund
S&P 500
This Quarter Est. Return
+6.17%
1 Year Est. Return
+33.63%
3 Year Est. Return
+104.86%
5 Year Est. Return
+133.18%
10 Year Est. Return
+557.96%
AUM
$144B
AUM Growth
+$27.9B
Cap. Flow
+$22.2B
Cap. Flow %
15.4%
Top 10 Hldgs %
31.02%
Holding
7,740
New
680
Increased
3,884
Reduced
2,259
Closed
408

Sector Composition

Rank Sector Weight
1 Technology 8.24%
2 Financials 5.68%
3 Healthcare 5.62%
4 Consumer Discretionary 5.04%
5 Industrials 3.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RPD icon
6126
CALL
Rapid7
RPD
$762M
$37K ﹤0.01%
+1,000
New +$33.6K
SPRO icon
6127
Spero Therapeutics
SPRO
$71.8M
$37K ﹤0.01%
3,557
+3,069
+629% +$35.6K
ULBI icon
6128
Ultralife
ULBI
$111M
$37K ﹤0.01%
4,510
+4,475
+12,786% +$41.8K
YARW
6129
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$37K ﹤0.01%
+1
New +$30.9K
MBII
6130
DELISTED
Marrone Bio Innovations, Inc.
MBII
$37K ﹤0.01%
20,451
+16,447
+411% +$31.9K
TBIO
6131
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$37K ﹤0.01%
+3,671
New +$42.7K
ZAGG
6132
PUT
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
$37K ﹤0.01%
2,500
-500
-17% -$7.95K
PRNB
6133
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$37K ﹤0.01%
+1,255
New +$35.4K
TIVO
6134
CALL
DELISTED
Tivo Inc
TIVO
$37K ﹤0.01%
+3,000
New +$38.8K
ROX
6135
DELISTED
Castle Brands, Inc.
ROX
$37K ﹤0.01%
34,567
+27,906
+419% +$31.8K
ISRL
6136
DELISTED
Isramco Inc
ISRL
$37K ﹤0.01%
306
+265
+646% +$31.6K
FCEL icon
6137
FuelCell Energy
FCEL
$1.62B
$36K ﹤0.01%
95
+78
+459% +$33.7K
GREK
6138
CALL
Global X MSCI Greece ETF
GREK
$329M
$36K ﹤0.01%
1,467
+800
+120% +$21.2K
MANU icon
6139
Manchester United
MANU
$3.72B
$36K ﹤0.01%
+1,589
New +$36.3K
MBIO icon
6140
Mustang Bio
MBIO
$4.46M
$36K ﹤0.01%
8
+6
+300% +$30K
NG icon
6141
CALL
NovaGold Resources
NG
$3.38B
$36K ﹤0.01%
9,700
+2,000
+26% +$8.06K
WGO icon
6142
CALL
Winnebago Industries
WGO
$905M
$36K ﹤0.01%
1,100
-102,500
-99% -$3.96M
AE
6143
DELISTED
Adams Resources & Energy Inc
AE
$36K ﹤0.01%
869
+710
+447% +$30.3K
GSKY
6144
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
$36K ﹤0.01%
2,000
-8,245
-80% -$157K
XONE
6145
CALL
DELISTED
The ExOne Company
XONE
$36K ﹤0.01%
3,800
+600
+19% +$4.85K
AWI icon
6146
CALL
Armstrong World Industries
AWI
$7.74B
$35K ﹤0.01%
+500
New +$34.5K
CELH icon
6147
Celsius Holdings
CELH
$6.68B
$35K ﹤0.01%
25,797
+20,766
+413% +$30.6K
DCI icon
6148
PUT
Donaldson
DCI
$11.2B
$35K ﹤0.01%
+600
New +$30.1K
EDC icon
6149
Direxion Daily MSCI Emerging Markets Bull 3X ETF
EDC
$158M
$35K ﹤0.01%
+416
New +$36.7K
UBX
6150
DELISTED
Unity Biotechnology
UBX
$35K ﹤0.01%
213
+56
+36% +$9.22K

Similar funds

Barclays's Q3 2018 Portfolio in Review

As of Q3 2018, Barclays held 7,740 positions worth $144B, up 24% from $116B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Barclays deployed $22.2B of net new capital in Q3 2018, opening 680 new positions and adding to 3,884 existing holdings. Its largest new stake was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.

By sector, the portfolio is most concentrated in Technology at 8.2% of assets, up from 7.4% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Weyerhaeuser, an estimated $431M trimmed.

  • Barclays's largest Q3 2018 buy was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
  • Barclays added most to Fortive in Q3 2018, an estimated $1.27B increase.
  • Barclays's biggest Q3 2018 reduction was Weyerhaeuser, cutting an estimated $431M.
  • Barclays fully exited Validus Hold Ltd in Q3 2018, selling an estimated $71M.
  • Barclays's ten largest holdings make up 31% of its $144B portfolio in Q3 2018.
  • Barclays opened 680 new positions and closed 408 in Q3 2018.
  • Barclays's portfolio value rose 24% quarter-over-quarter to $144B.

Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.